Eurartesim® (dihydroartemisinin-piperaquine) for the treatment of acute uncomplicated P. falciparum malaria

According to the WHO, malaria affected 229 million people worldwide in 2019, resulting in 409,000 deaths. Timely access to appropriate treatment is key to ensuring a bout of acute uncomplicated malaria does not turn into a severe case. 

Eurartesim protects patients from new malaria infections for an extended period 

Eurartesim is a fixed-dose combination of dihydroartemisinin-piperaquine (DHA-PQP), developed by Alfasigma S.p.A. in partnership with MMV, for the treatment of acute uncomplicated P. falciparum malaria. Eurartesim is administered once a day over 3 days. Studies have shown that Eurartesim’s long half-life affords patients a useful period of protection from new malaria infections.1 

An essential medicine recommended by WHO  

In October 2011, the European Medicines Agency (EMA) granted marketing authorization for Eurartesim. In October 2015, Eurartesim was prequalified by WHO and, in June 2017, DHA-PQP was added to WHO’s Model List of Essential Medicines (EML) and Model List of Essential Medicines for Children (EMLc) after a successful application to the EML by Alfasigma. 

Eurartesim is available in 32 African countries  

In 2015, Alfasigma entered into an exclusive licensing agreement with Pierre Fabre to expand its ability to support country registration requirements and national adoption of Eurartesim in 32 African countries. Over 4.5 million treatments of Eurartesim have been distributed since approval by the EMA. 

Alfasigma will submit a regulatory dossier to the EMA for a new dispersible formulation of Eurartesim designed specifically to address the treatment needs of children. 

  • Past and current partners:

    Alfasigma S.p.A, INDEPTH Effectiveness and Safety Studies (INESS), Malaria Control and Elimination Partnership in Africa (MACEPA), Liverpool School of Tropical Medicine, Ministry of Health Cambodia (National Center for Malaria Control, Parasitology and Entomology – CNM; and the Department of Drugs and Food – DDF), Pierre Fabre, Population Services International (Cambodia and Kenya), The Global Fund to Fight AIDS Tuberculosis and Malaria, World Health Organization (Geneva and Cambodia), IsGlobal and The London School of Hygiene and Tropical Medicine.

     1. Valecha Net et al., An open-label, randomised study of dihydroartemisinin-piperaquine versus artesunate-mefloquine for falciparum malaria in Asia. PLoS One. 5(7):e11880 (2010); Bassat Q, Mulenga M, Tinto H, Piola P, Borrmann S, et al.  Dihydroartemisinin-Piperaquine and Artemether-Lumefantrine for Treating Uncomplicated Malaria in African Children: A Randomised, Non-Inferiority Trial. PLoS ONE 4(11): e7871 (2009). doi: 10.1371/journal.pone.0007871.


    Updated November 2020